Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Clinical Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0009922809332682v1
48/7/734    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Scalabrin, D. M.
Right arrow Articles by Mitmesser, S. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scalabrin, D. M.
Right arrow Articles by Mitmesser, S. H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Growth and Tolerance of Healthy Term Infants Receiving Hydrolyzed Infant Formulas Supplemented With Lactobacillus rhamnosus GG: Randomized, Double-Blind, Controlled Trial

Deolinda M. Scalabrin, MD, PhD

Department of Medical Affairs, Mead Johnson Nutrition, Evansville, Indiana

William H. Johnston, MD

Birmingham Pediatric Group, Birmingham, Alabama

Dennis R. Hoffman, PhD

Retina Foundation of the Southwest, Dallas, Texas

Virginia L. P'Pool, RN

Department of Medical Affairs, Mead Johnson Nutrition, Evansville, Indiana

Cheryl L. Harris, MS

Department of Medical Affairs, Mead Johnson Nutrition, Evansville, Indiana

Susan H. Mitmesser, PhD

Department of Medical Affairs, Mead Johnson Nutrition, Evansville, Indiana, susan.mitmesser{at}mjn.com

Healthy, term infants received extensively hydrolyzed casein formula (EHF; control), the same formula supplemented with Lactobacillus rhamnosus GG (EHF-LGG), or partially hydrolyzed whey:casein (60:40) formula supplemented with LGG (PHF-LGG), in this double-blind, randomized, controlled, parallel, prospective study. Anthropometric measures and 24-hour dietary and tolerance recalls were obtained at 30, 60, 90, 120, and 150 days of age. Blood collected in a subset of infants was analyzed for fatty acid profiles in plasma and red blood cells and for markers of allergic sensitization. Adverse events were recorded throughout the study. Growth rates were not statistically different between EHF and PHF-LGG and between EHF and EHF-LGG from day 14 to day 30, 120, or 150. No relevant differences in formula tolerance, adverse events, or allergic and immune markers were demonstrated between groups. The extensively and partially hydrolyzed formulas supplemented with LGG support normal growth in healthy, term infants and are well tolerated and safe.

Key Words: infant formula • extensively hydrolyzed formula • partially hydrolyzed formula • LGG • infant growth • allergy • polyunsaturated fatty acids

This version was published on September 1, 2009

Clinical Pediatrics, Vol. 48, No. 7, 734-744 (2009)
DOI: 10.1177/0009922809332682
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?